IL205607A0 - Axl antibodies - Google Patents

Axl antibodies

Info

Publication number
IL205607A0
IL205607A0 IL205607A IL20560710A IL205607A0 IL 205607 A0 IL205607 A0 IL 205607A0 IL 205607 A IL205607 A IL 205607A IL 20560710 A IL20560710 A IL 20560710A IL 205607 A0 IL205607 A0 IL 205607A0
Authority
IL
Israel
Prior art keywords
axl antibodies
axl
antibodies
Prior art date
Application number
IL205607A
Other languages
English (en)
Original Assignee
U3 Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U3 Pharma Gmbh filed Critical U3 Pharma Gmbh
Publication of IL205607A0 publication Critical patent/IL205607A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL205607A 2007-11-12 2010-05-06 Axl antibodies IL205607A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07021931 2007-11-12
PCT/EP2008/009548 WO2009062690A1 (en) 2007-11-12 2008-11-12 Axl antibodies

Publications (1)

Publication Number Publication Date
IL205607A0 true IL205607A0 (en) 2010-11-30

Family

ID=40280763

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205607A IL205607A0 (en) 2007-11-12 2010-05-06 Axl antibodies

Country Status (19)

Country Link
US (1) US8933202B2 (https=)
EP (2) EP2220121B1 (https=)
JP (2) JP5769969B2 (https=)
KR (1) KR20100097684A (https=)
CN (2) CN101939336B (https=)
AU (1) AU2008323206B2 (https=)
BR (1) BRPI0820073A2 (https=)
CA (1) CA2705164A1 (https=)
CO (1) CO6280499A2 (https=)
DK (1) DK2220121T3 (https=)
ES (1) ES2556214T3 (https=)
IL (1) IL205607A0 (https=)
MX (1) MX2010005031A (https=)
MY (1) MY155621A (https=)
NZ (2) NZ585465A (https=)
RU (1) RU2506276C2 (https=)
SG (2) SG10201405835TA (https=)
WO (1) WO2009062690A1 (https=)
ZA (1) ZA201003397B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5769969B2 (ja) * 2007-11-12 2015-08-26 ユー３・ファーマ・ゲーエムベーハー Ａｘｌ抗体
AU2008321835B2 (en) 2007-11-15 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
CA2759836A1 (en) * 2009-05-11 2010-11-18 U3 Pharma Gmbh Humanized axl antibodies
EP2270053A1 (en) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
KR20120024763A (ko) 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
EP2483289B2 (en) 2009-10-02 2025-03-26 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
PT2525824T (pt) * 2010-01-22 2017-07-13 Univ Leland Stanford Junior Inibição da sinalização de axl em terapêutica antimetastática
CN101858917B (zh) * 2010-06-02 2013-03-27 成都创宜生物科技有限公司 Axl单克隆抗体的应用及以Axl为检测指标的胎膜早破检测试剂盒和制备方法
RU2577986C2 (ru) 2010-06-18 2016-03-20 Дженентек, Инк. Антитела против axl и способы их применения
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012158551A1 (en) 2011-05-13 2012-11-22 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
ES2989943T3 (es) * 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
CA2839508A1 (en) * 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) * 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
JP6195716B2 (ja) * 2013-02-15 2017-09-13 富士レビオ株式会社 抗癌剤耐性診断マーカー
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410826D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
DK4074735T3 (da) 2014-08-28 2025-07-14 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
JP6864953B2 (ja) * 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
AU2015366213B2 (en) 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
EP4679095A3 (en) 2015-05-18 2026-05-06 Agensys, Inc. Antibodies that bind to axl proteins
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
PL3319993T3 (pl) * 2015-07-10 2020-07-27 Genmab A/S Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
SMT202600033T1 (it) 2016-04-15 2026-03-09 Bioatla Inc Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi
PL3455261T3 (pl) 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
JP7280827B2 (ja) 2017-01-18 2023-05-24 エクスマ バイオテック コーポレイション Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109160941B (zh) * 2018-09-29 2020-09-04 未名生物医药有限公司 蛋白序列17e11及其用途
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
EP4132652A1 (en) 2020-04-08 2023-02-15 BerGenBio ASA Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
US20250019446A1 (en) * 2021-06-16 2025-01-16 Shanghai Sinobay Biotechnology Co., Ltd. Antibody Targeting Axl Protein and Antigen Binding Fragment Thereof, and Preparation Method Therefor and Application Thereof
CN116348497B (zh) * 2023-01-05 2023-11-17 浙江时迈药业有限公司 针对axl的抗体及其用途
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4931385A (en) 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
AU4541093A (en) 1992-06-18 1994-01-24 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
KR100308764B1 (ko) 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
WO1997034636A1 (en) * 1996-03-20 1997-09-25 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
JPH1084958A (ja) * 1996-09-17 1998-04-07 Pola Chem Ind Inc 抗繊維芽細胞増殖因子６モノクローナル抗体
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU5597500A (en) * 1999-06-07 2000-12-28 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
PT1848744E (pt) * 2005-01-27 2012-04-24 Novimmune Sa Anticorpos anti-interferão gama e os seus processos de utilização
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
KR101457223B1 (ko) * 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
NZ566774A (en) * 2005-09-07 2011-11-25 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1
EP1789435B1 (en) * 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
CA2692320A1 (en) * 2007-07-02 2009-01-08 Wyeth Methods of treating bone disorders with modulators of axl
EP2219671A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
JP5769969B2 (ja) 2007-11-12 2015-08-26 ユー３・ファーマ・ゲーエムベーハー Ａｘｌ抗体
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
AU2008323206A1 (en) 2009-05-22
JP2011505120A (ja) 2011-02-24
EP2918605A1 (en) 2015-09-16
CO6280499A2 (es) 2011-05-20
SG10201405835TA (en) 2014-10-30
CA2705164A1 (en) 2009-05-22
CN101939336A (zh) 2011-01-05
MY155621A (en) 2015-11-13
CN103275227B (zh) 2015-02-11
KR20100097684A (ko) 2010-09-03
RU2506276C2 (ru) 2014-02-10
EP2220121B1 (en) 2015-08-19
NZ585465A (en) 2012-12-21
EP2220121A1 (en) 2010-08-25
SG186000A1 (en) 2012-12-28
ES2556214T3 (es) 2016-01-14
RU2010123888A (ru) 2011-12-20
JP2015221804A (ja) 2015-12-10
US8933202B2 (en) 2015-01-13
CN101939336B (zh) 2014-05-14
ZA201003397B (en) 2011-04-28
CN103275227A (zh) 2013-09-04
JP5769969B2 (ja) 2015-08-26
WO2009062690A1 (en) 2009-05-22
DK2220121T3 (en) 2015-12-07
HK1185622A1 (en) 2014-02-21
HK1147275A1 (en) 2011-08-05
BRPI0820073A2 (pt) 2015-06-23
US20100330095A1 (en) 2010-12-30
MX2010005031A (es) 2010-06-25
NZ599628A (en) 2013-11-29
AU2008323206B2 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
IL205607A0 (en) Axl antibodies
GB0708002D0 (en) Antibodies
SI2146745T1 (sl) Penta-specifično protitelo
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
SI2200700T1 (sl) Nova protitelesa
GB0821100D0 (en) Antibodies
GB2448914B (en) Vehicle
EP2163467A4 (en) VEHICLE
ZA200905598B (en) Vehicle
GB0718737D0 (en) Antibodies
IL207581A0 (en) Anti-tyrp1 antibodies
IL205073A0 (en) Anti-bst2 antibody
GB0702888D0 (en) Novel Antibodies
ZA201007976B (en) Anti-pirb antibodies
EP2202366A4 (en) SUSPENSION DEVICE
EP2194815A4 (en) BED-VEHICLE BED
GB0818356D0 (en) Antibodies
GB0701067D0 (en) Improved vehicles
GB2446009B (en) Improved vehicles
GB0911770D0 (en) Antibody
GB2449333B (en) Appetite-control aid
GB2449050B (en) Shoping aid
GB0724185D0 (en) Antibodies
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies